CAT and prostate cancer: Our data showing that AR activation reduces CAT levels and activity in LNCaP cells (Figure 11 and Figure 12) suggest that the differences in CAT levels between cultured cells and patient prostate tissue may be attributed to the significantly higher androgen levels present in prostate cancer tissue compared to standard cell culture media [49].